Zhang Jing

68 statements · 1 topic · summaries given as host listed separately

Biliary Atresia · guest expert

Featured statements

▶ Ep 20 · 6:14
And I think, uh, nowadays it's CSI procedure is still the first line treatment for bilireatresia, but as we can see, there's some patients, um, could not achieve their jaundice clearance and their um they couldn't live long for uh with their native liver.
▶ Ep 20 · 0:48
Recently, it has been reported that MMP 7 can help precisely discriminate BA from other cholecystic diseases at a cutoff value of around 20.

Nothing matches these filters — clear the search or widen the filters.

Zhang's statements about Biliary Atresia 68 statements

Open the Biliary Atresia collection →

Jingying Jiang, MD - Best of the Best in Pediatric Surgery 2024

▶ Ep 20 · 0:42
quote Breatresia is a severe liver disease characterized by fibro inflammatory destruction of bi ducts. ↗
▶ Ep 20 · 0:42
clinical Biliary atresia is a severe liver disease characterized by fibro-inflammatory destruction of bile ducts. ↗
▶ Ep 20 · 0:42
quote Breatresia is a severe liver disease characterized by fibro inflammatory destruction of bi ducts. ↗
▶ Ep 20 · 0:42
clinical Biliary atresia is a severe liver disease characterized by fibro-inflammatory destruction of bile ducts. ↗
▶ Ep 20 · 0:48
clinical MMP-7 can help precisely discriminate BA from other cholestatic diseases at a cutoff value of around 20 ng/mL. ↗
▶ Ep 20 · 0:48
quote Recently, it has been reported that MMP 7 can help precisely discriminate BA from other cholecystic diseases at a cutoff value of around 20. ↗
▶ Ep 20 · 1:00
quote However, there were Still 5 to 10% of patients with force negative MMP7 whose characteristics and prognosis remain unknown. ↗
▶ Ep 20 · 1:00
epidemiological 5 to 10% of BA patients have false negative MMP-7 levels. ↗
▶ Ep 20 · 1:24
clinical The study reviewed 329 BA patients who underwent Kasai procedure from 2020 to 2022. ↗
▶ Ep 20 · 1:24
clinical The study reviewed 329 BA patients who underwent Kasai procedure from 2020 to 2022. ↗
▶ Ep 20 · 1:34
clinical Patients were divided into low MMP-7 and high MMP-7 groups based on preoperative MMP-7 levels of 20-25 ng/mL. ↗
▶ Ep 20 · 1:34
clinical Patients were divided into low MMP-7 and high MMP-7 groups based on preoperative MMP-7 levels of 20-25 ng/mL. ↗
▶ Ep 20 · 2:03
clinical The median MMP-7 level for low MMP-7 group was 20.19 ng/mL compared with 66.55 ng/mL for the high MMP-7 group. ↗
▶ Ep 20 · 2:03
clinical The median MMP-7 level for low MMP-7 group was 20.19 ng/mL compared with 66.55 ng/mL for the high MMP-7 group. ↗
▶ Ep 20 · 2:16
clinical Preoperative gamma-GT and direct bilirubin in the low MMP-7 group were significantly lower than those in the high MMP-7 group. ↗
▶ Ep 20 · 2:16
clinical Preoperative gamma-GT and direct bilirubin in the low MMP-7 group were significantly lower than those in the high MMP-7 group. ↗
▶ Ep 20 · 2:26
clinical Fibrosis stages were significantly different between the low and high MMP-7 groups. ↗
▶ Ep 20 · 2:26
clinical Fibrosis stages were significantly different between the low and high MMP-7 groups. ↗
▶ Ep 20 · 2:34
clinical Three-month jaundice clearance rate was 46.91% for the high MMP-7 group and 29.73% for the low MMP-7 group. ↗
▶ Ep 20 · 2:34
clinical Three-month jaundice clearance rate was 46.91% for the high MMP-7 group and 29.73% for the low MMP-7 group. ↗
▶ Ep 20 · 2:50
clinical Six-month jaundice clearance rate was 54.51% for the high MMP-7 group and 32.14% for the low MMP-7 group. ↗
▶ Ep 20 · 2:50
clinical Six-month jaundice clearance rate was 54.51% for the high MMP-7 group and 32.14% for the low MMP-7 group. ↗
▶ Ep 20 · 3:03
clinical A total of 90 patients in the low MMP-7 group and 112 patients in the high MMP-7 group died or underwent liver transplantation by the latest follow-up. ↗
▶ Ep 20 · 3:03
clinical A total of 90 patients in the low MMP-7 group and 112 patients in the high MMP-7 group died or underwent liver transplantation by the latest follow-up. ↗
▶ Ep 20 · 3:16
clinical One-year native liver survival rate was 29.63% for the low MMP-7 group and 53.02% for the high MMP-7 group. ↗
▶ Ep 20 · 3:16
clinical One-year native liver survival rate was 29.63% for the low MMP-7 group and 53.02% for the high MMP-7 group. ↗
▶ Ep 20 · 3:29
quote So taken together, around 10% of VA patients have low 7 MMP 7 levels. ↗
▶ Ep 20 · 3:29
quote So taken together, around 10% of VA patients have low 7 MMP 7 levels. ↗
▶ Ep 20 · 3:29
epidemiological Around 10% of BA patients have low MMP-7 levels. ↗
▶ Ep 20 · 3:29
epidemiological Around 10% of BA patients have low MMP-7 levels. ↗
▶ Ep 20 · 3:41
quote Our previous study suggested. Low gamma GT levels correlated with more severe liver injury and poor outcomes. ↗
▶ Ep 20 · 3:41
clinical Low gamma-GT levels correlated with more severe liver injury and poor outcomes in a previous study. ↗
▶ Ep 20 · 3:50
clinical BA patients in the low MMP-7 group had a lower jaundice clearance rate and native liver survival rate. ↗
▶ Ep 20 · 3:50
clinical BA patients in the low MMP-7 group had a lower jaundice clearance rate and native liver survival rate. ↗
▶ Ep 20 · 3:59
quote So more subjects and a long-term follow-up are warranted to determine whether this could be listed as a new clinical subtype of BA. ↗
▶ Ep 20 · 3:59
quote So more subjects and a long-term follow-up are warranted to determine whether this could be listed as a new clinical subtype of BA. ↗
▶ Ep 20 · 4:11
quote One of our limitations in this study was the period of follow-up maybe not long enough for some patients, ranging from 3 months to 3 years, and some patients lost follow up within 3 months and were excluded from final analysis which may Introduceed buyers to the results. ↗
▶ Ep 20 · 4:11
quote One of our limitations in this study was the period of follow-up maybe not long enough for some patients, ranging from 3 months to 3 years, and some patients lost follow up within 3 months and were excluded from final analysis which may Introduceed buyers to the results. ↗
▶ Ep 20 · 4:11
clinical Some patients lost to follow-up within 3 months were excluded from final analysis. ↗
▶ Ep 20 · 4:11
clinical The follow-up period ranged from 3 months to 3 years. ↗
▶ Ep 20 · 4:11
clinical The follow-up period ranged from 3 months to 3 years. ↗
▶ Ep 20 · 4:11
clinical Some patients lost to follow-up within 3 months were excluded from final analysis. ↗
▶ Ep 20 · 4:30
clinical Patients did not take MMP-7 measurements post-Kasai procedure in this study. ↗
▶ Ep 20 · 4:30
clinical Patients did not take MMP-7 measurements post-Kasai procedure in this study. ↗
▶ Ep 20 · 4:30
quote Finally, the patients did not take MMP 7 measurements post Kasa procedure. ↗
▶ Ep 20 · 4:30
quote Finally, the patients did not take MMP 7 measurements post Kasa procedure. ↗
▶ Ep 20 · 4:36
quote However, the dynamic analysis of MMP 7 levels postoperatively will be meaningful in further understanding the mechanism. ↗
▶ Ep 20 · 4:36
quote However, the dynamic analysis of MMP 7 levels postoperatively will be meaningful in further understanding the mechanism. ↗
▶ Ep 20 · 5:26
clinical MMP-7 measurement is based on ELISA method. ↗
▶ Ep 20 · 5:26
clinical MMP-7 measurement is based on ELISA method. ↗
▶ Ep 20 · 5:26
quote So, the MMP 7 measurement is based on the 7, and, uh, it is based on the method of Eliza. ↗
▶ Ep 20 · 5:26
quote So, the MMP 7 measurement is based on the 7, and, uh, it is based on the method of Eliza. ↗
▶ Ep 20 · 5:36
clinical MMP-7 testing is not very popular in every hospital in China, just in some institutions. ↗
▶ Ep 20 · 5:36
clinical MMP-7 testing is not very popular in every hospital in China, just in some institutions. ↗
▶ Ep 20 · 5:44
clinical MMP-7 testing costs about 1000 RMB per patient in China. ↗
▶ Ep 20 · 5:44
clinical MMP-7 testing costs about 1000 RMB per patient in China. ↗
▶ Ep 20 · 5:44
quote So it's cost about uh I think 1000 RMB for each patient, uh, each measurement. ↗
▶ Ep 20 · 5:44
quote So it's cost about uh I think 1000 RMB for each patient, uh, each measurement. ↗
▶ Ep 20 · 6:14
quote And I think, uh, nowadays it's CSI procedure is still the first line treatment for bilireatresia, but as we can see, there's some patients, um, could not achieve their jaundice clearance and their um they couldn't live long for uh with their native liver. ↗
▶ Ep 20 · 6:14
guideline Kasai procedure is still the first line treatment for biliary atresia. ↗
▶ Ep 20 · 6:14
clinical Some BA patients could not achieve jaundice clearance and could not live long with their native liver after Kasai. ↗
▶ Ep 20 · 6:14
quote And I think, uh, nowadays it's CSI procedure is still the first line treatment for bilireatresia, but as we can see, there's some patients, um, could not achieve their jaundice clearance and their um they couldn't live long for uh with their native liver. ↗
▶ Ep 20 · 6:14
guideline Kasai procedure is still the first line treatment for biliary atresia. ↗
▶ Ep 20 · 6:14
clinical Some BA patients could not achieve jaundice clearance and could not live long with their native liver after Kasai. ↗
▶ Ep 20 · 6:34
opinion If the mechanism of MMP-7 in biliary atresia becomes clear, patients with low MMP-7 might go directly for liver transplantation in the future. ↗
▶ Ep 20 · 6:34
quote So someday if we are definitely uh clear about their mechanism of MMP 7 in bilireresia, maybe someday, the patients with low MMP 7 can go directly for liver transplantation. ↗
▶ Ep 20 · 6:34
quote So someday if we are definitely uh clear about their mechanism of MMP 7 in bilireresia, maybe someday, the patients with low MMP 7 can go directly for liver transplantation. ↗
▶ Ep 20 · 6:34
opinion If the mechanism of MMP-7 in biliary atresia becomes clear, patients with low MMP-7 might go directly for liver transplantation in the future. ↗

Summaries Zhang gave as host · 6 summaries

Recaps of other experts' statements, not Zhang's own clinical position.

Summaries Zhang gave as host · Biliary Atresia 6 summaries

Open the Biliary Atresia collection →

Jingying Jiang, MD - Best of the Best in Pediatric Surgery 2024

▶ Ep 20 · 0:48
host summary Zhang Jing summarizing a resource: MMP-7 can help precisely discriminate BA from other cholestatic diseases at a cutoff value of around 20 ng/mL. ↗
▶ Ep 20 · 0:48
host summary Zhang Jing summarizing a resource: Recently, it has been reported that MMP 7 can help precisely discriminate BA from other cholecystic diseases at a cutoff value of around 20. ↗
▶ Ep 20 · 1:00
host summary Zhang Jing summarizing a resource: However, there were Still 5 to 10% of patients with force negative MMP7 whose characteristics and prognosis remain unknown. ↗
▶ Ep 20 · 1:00
host summary Zhang Jing summarizing a resource: 5 to 10% of BA patients have false negative MMP-7 levels. ↗
▶ Ep 20 · 3:41
host summary Zhang Jing summarizing a resource: Our previous study suggested. Low gamma GT levels correlated with more severe liver injury and poor outcomes. ↗
▶ Ep 20 · 3:41
host summary Zhang Jing summarizing a resource: Low gamma-GT levels correlated with more severe liver injury and poor outcomes in a previous study. ↗